# Study of Intravenous Immunoglobulin in Amnestic Mild Cognitive Impairment

> **NCT01300728** · PHASE2 · COMPLETED · sponsor: **Sutter Health** · enrollment: 52 (actual)

## Conditions studied

- Mild Cognitive Impairment

## Interventions

- **DRUG:** NewGam 10% IVIG
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT01300728
- **Lead sponsor:** Sutter Health
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-01-01
- **Primary completion:** 2020-03-12
- **Final completion:** 2020-03-12
- **Target enrollment:** 52 (ACTUAL)
- **Last updated:** 2022-10-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01300728

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01300728, "Study of Intravenous Immunoglobulin in Amnestic Mild Cognitive Impairment". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01300728. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*